Overview

Anecortave Acetate Risk Reduction Trial (AART)

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.

Phase:

Phase 3

Details

Lead Sponsor:

Alcon Research

Treatments:

Anecortave
Hydrocortisone